Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 172   

Articles published

BMY 56.05 +0.38 (0.68%)
price chart
Bristol Myers Squibb buoyed by surge in sales of key drugs
Bristol Myers Squibb Co (NYSE:BMY) was set for a strong start as first quarter earnings beat forecasts on the back of booming sales of key cancer drug Opdivo and blood thinner Eliquis.
Bristol-Myers Squibb Co. Reveals 13% Rise In Q1 Bottom Line  Nasdaq
Bristol-Myers Squibb Reports First Quarter Financial Results  Yahoo Finance
Bristol-Myers Squibb stock surges 3% after first-quarter profit, revenue beats
Bristol-Myers Squibb Co. BMY, +3.53% shares surged 3.2% in premarket trade Thursday after the company reported first-quarter profit and revenue beats.
Quadrant Capital Group LLC Has $607000 Position in Bristol-Myers Squibb Co (BMY)
Bristol-Myers Squibb logo Quadrant Capital Group LLC lowered its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 0.4% during the first quarter, according to its most recent 13F filing with the SEC.
European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab ...  Business Wire (press release)
Bristol-Myers Squibb: Strong Earnings Could Warrant Higher Dividend Growth Ahead  Yahoo Finance
China FDA Approves Country's First All-Oral Regimen for Chronic Hepatitis C ...
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that the China Food and Drug Administration (CFDA) has approved a direct-acting antiviral regimen comprised of Daklinza� (daclatasvir) and Sunvepra� ...
China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis C Treatment  Wall Street Journal (subscription)
Bristol-Myers wins approval in China for oral treatment for chronic ...  MarketWatch
Bristol-Myers Squibb Co: Buy the Dip?
Shares of Bristol-Myers Squibb (NYSE:BMY) have slipped about 30% since the company announced a surprising setback for its lead growth driver, Opdivo, last August.
What makes Bristol-Myers Squibb Company (BMY) a good dividend stock?  Simply Wall St
Bristol-Myers Squibb (BMY): Takeout Unlikely - BMO  StreetInsider.com
What Analysts Expect of Bristol-Myers Squibb's 1Q17 Earnings
Headquartered in New York City, Bristol-Myers Squibb (BMY) is an American pharmaceutical company that deals with innovative medicines for patients with serious diseases in therapeutic areas such as virology, oncology, cardiovascular therapy, ...
Analyst Activity – Robert W. Baird Initiates Coverage On Bristol-Myers ...  Market Exclusive
Bristol-Myers Squibb says cancer drug combination 'significantly' improved ...
Bristol-Myers Sqibb Co. BMY, +3.53% said Monday morning that the combination of its two cancer drugs showed the best survival rates in melanoma patients in a late-stage clinical trial.
Bristol-Myers Squibb Trades Ex-Dividend Wednesday (BMY)  Investopedia
Ex-Dividend Reminder: Morningstar, American Eagle Outfitters and Bristol ...  Nasdaq
Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to ...
NEW YORK & STRASBOURG, France--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Transgene today announced a new clinical research collaboration to evaluate the safety, tolerability and efficacy of Transgene's investigational ...
Penn Davis Mcfarland Inc Buys Celgene, Bristol-Myers Squibb Company, Sells ...
Penn Davis Mcfarland Inc initiated holdings in Celgene Corp. The purchase prices were between $111.53 and $126.88, with an estimated average price of $119.67.
Bristol-Myers Squibb Company (BMY) Ex-Dividend Date Scheduled for April 05, 2017
Bristol-Myers Squibb Company ( BMY ) will begin trading ex-dividend on April 05, 2017. A cash dividend payment of $0.39 per share is scheduled to be paid on May 01, 2017.
Bristol-Myers Squibb Company subtracted -1.96% in its Stock Price in the ...  Free Observer
Just the Facts on Bristol-Myers Squibb Company (BMY)  StockNewsJournal